Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a Healthcare company (Biotechnology) with a market capitalization of $679M. The Maz Rating grades it against the other companies in its sector.
Attovia Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.86, Attovia Therapeutics, Inc. trades at 468.6x sales and 10.9x book value. Over the last twelve months it generated about $1M of revenue and a net loss of $83M. It runs a gross margin of 32.8%, an operating margin of -5945.5% and a net margin of -5477.2%. It shows return on equity of -58.9%, return on invested capital of -21.3% and a free cash flow yield of -11.6%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 34.66. Over the past 52 weeks the share price ranged from $12.94 to $28.00, with a beta of 0.00.
Attovia Therapeutics, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Attovia Therapeutics, Inc. (ATTO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.37% / 30% · Interest income / Revenue 278700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.37% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 278700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.37% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 278700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.47% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.4% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 278700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.1% / 33.33% · (Cash+Recv) / Total Assets 96.1% / 33.33% · Interest income / Revenue 278700000.0% / 5% | Fail |
No. As of September 2026, Attovia Therapeutics, Inc. (ATTO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Attovia Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 278700000.0% of each dividend: Attovia Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.